Ibrutinib Results Suggest Potential To Shake Up CLL Market
Executive Summary
Momentum builds for Pharmacyclics/J&J’s ibrutinib with release of new data at the American Society of Hematology meeting, suggesting the drug has a shot at accelerated approval in sub-populations with high unmet need and potential in a range of B-cell cancers. Profiles of competitors from Gilead and Infinity/Takeda also came into greater focus at ASH.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: